期刊
BIOSENSORS & BIOELECTRONICS
卷 208, 期 -, 页码 -出版社
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2022.114189
关键词
Adalimumab; Self-powered microfluidics; Point-of-care; Therapeutic drug monitoring; Plasmapheresis; ELISA
类别
资金
- Research Foundation Flanders (FWO) [1S35118N, G084818N]
- KU Leuven [C32/17/007, C3/21/014, C24/16/022]
A novel self-powered microfluidic chip was developed for point-of-care therapeutic drug monitoring of adalimumab, enabling detection within 30 minutes directly from whole blood.
Therapeutic drug monitoring (TDM) of adalimumab (ADM) at the point-of-care (POC) is key to prevent loss of response but has not been accomplished to date because true POC testing solutions are still lacking. Here, we present a novel whole blood in - result out self-powered microfluidic chip for detecting ADM within 30 min to enable TDM at POC. Hereto, we first demonstrated on-chip plasma separation from whole blood, followed by downscaling an ADM ELISA with maintained specificity and sensitivity in plasma. This assay was then performed on a robust and easy-to-use microfluidic chip we designed based on (i)SIMPLE technology, allowing autonomous function upon single finger press activation, which was successfully validated with patient samples. Herein, we prove the potential of our technology to detect targets starting from whole blood introduced directly on-chip and to integrate various immunoassays, both for TDM and other in vitro diagnostics applications, like infectious diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据